June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Effects of a proprietary de-novo IOP lowering compound (ID-65-CW69) on aqueous humor dynamics in monkeys
Author Affiliations & Notes
  • Shan Fan
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Lisa Reid
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Toni L. Goeser
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Ganesh Prasanna
    Ophthalmology Research, Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, United States
  • Carol B Toris
    Ophthalmology, University of Nebraska Medical Center, Omaha, Nebraska, United States
  • Footnotes
    Commercial Relationships   Shan Fan, None; Lisa Reid, None; Toni Goeser, None; Ganesh Prasanna, Novartis Institutes for Biomedical Research (E); Carol Toris, Novartis Institutes for Biomedical Research (F)
  • Footnotes
    Support  Novartis Institutes for Biomedical Research ; RPB
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 546. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shan Fan, Lisa Reid, Toni L. Goeser, Ganesh Prasanna, Carol B Toris; Effects of a proprietary de-novo IOP lowering compound (ID-65-CW69) on aqueous humor dynamics in monkeys. Invest. Ophthalmol. Vis. Sci. 2021;62(8):546.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to identify the mechanism by which a novel selective soluble guanylate cyclase activator (ID-65-CW69) lowers intraocular pressure (IOP) and alters aqueous humor dynamics in monkeys with unilateral laser induced glaucoma.

Methods : Fifteen female cynomolgus monkeys with unilateral laser-induced glaucoma were dosed with one 30 µl drop of ID-65-CW69 or its vehicle to the cornea of both eyes at 6:00 PM the day before the measurement day in a masked crossover fashion. Intraocular pressures (mmHg) were measured by pneumatonometry at 6:00 PM (IOP1), just before dosing; and again at10:00AM (IOP2) and noon (IOP3) the following day. Other measurements were aqueous flow (Fa, μl/min) by fluorophotometry, outflow facility (C, μl/min/mmHg) by fluorophotometry (C) and uveoscleral outflow (Fu, μl/min) by mathematical calculation.

Results : The hypertensive eyes showed a significant decrease in IOP to the level of the normotensive eyes. Results in the hypertensive eyes are summarized in the Table. Values are Means±SD. Drug treatments and corresponding vehicle treatments were compared by two-tailed paired t-tests (p). No significant changes were found in the normotensive eyes.

Conclusions : ID-65-CW69 reduced IOP in hypertensive eyes by increasing uveoscleral outflow by over two-fold. Outflow facility increased but this did not reach significance. The drug did not significantly lower IOP in the normotensive eyes.

This is a 2021 ARVO Annual Meeting abstract.

 

Hypertensive eyes

Hypertensive eyes

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×